FDA Should Cite Regulatory Imperative When Narrowing 510(k) Claims – Cook
This article was originally published in The Gray Sheet
Executive Summary
FDA should consult with a three-person "supervisory" panel in deciding whether to narrow a proposed indication statement for 510(k) devices, Cook Group, Inc. suggests in March 4 comments to HHS Secretary Thompson's regulatory reform advisory committee
You may also be interested in...
FDAMA In Action? ODE Shows Progress On IDE Supplements, Five-Day Notice
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”